... advantageous to a buyer because of tax reasons, but it is reduced pursuant to Pfizer's (NYSE:PFE) failed reverse merger with Allergan (NYSE:AGN). ...read more
Growth Capitalist (https://growthcapitalist.com/2016/10/with-nxp-semiconductors-qualcomm-may-be-considering-freescales-patents/)
... advantageous to a buyer because of tax reasons, but it is reduced pursuant to Pfizer's (NYSE:PFE) failed reverse merger with Allergan (NYSE:AGN). ...read more